BrightHeart, a medtech company building artificial intelligence software for prenatal ultrasound, has raised €11 million in a Series A funding round to accelerate its expansion across the United States and Europe.
The company focuses on improving how congenital heart defects are detected during pregnancy. By embedding AI directly into routine ultrasound exams, Bright Heart helps OB-GYNs deliver expert-level screening for complex organs, particularly the fetal heart, without changing how clinicians already work.
€11M Series A co-led by Odyssée Venture and GO Capital
The Series A round was co-led by Odyssée Venture and GO Capital, with participation from the Mussallem CHD Alliance, Lift Value, IDAHO HealthTech Club through Side Angels, and existing investor Sofinnova Partners.
The round also attracted prominent clinicians and angel investors, including Professor Laurent Salomon, former President of the International Society of Ultrasound in Obstetrics and Gynaecology, alongside serial medtech entrepreneurs Sacha Loiseau and John Gridley.
This mix of healthcare focused investors and clinical experts reflects growing confidence in Bright Heart’s regulatory progress, clinical evidence, and commercial potential.
AI software designed for real-world ultrasound workflows
BrightHeart has developed an AI software platform that supports clinicians throughout the entire ultrasound examination. The system provides real time guidance to ensure complete fetal heart screening, precise anatomical tracking, and faster, more consistent evaluations.
Unlike standalone tools, BrightHeart’s FDA-cleared medical devices integrate directly into existing ultrasound workflows. This approach helps improve exam completeness, reduce diagnostic errors, and save valuable clinical time, all while supporting confident decision-making.
Clinically validated improvements in congenital heart defect detection
The company’s technology has been clinically validated to achieve congenital heart defect detection rates of more than 96 per cent. The platform also reduces diagnostic errors and improves overall efficiency during prenatal exams.
The company has secured five FDA clearances and established partnerships with leading academic centres. It has also published two peer-reviewed clinical studies in Obstetrics & Gynaecology, making BrightHeart the only company in its field with published peer-reviewed clinical evidence.
Also Read: Tucuvi: Building Europe’s First Certified Clinical Voice AI with €17M to Transform Patient Care
Funding to support US commercialisation and European growth
The new funding will be used to support commercial rollout in the United States, expansion across European markets, and continued product development. BrightHeart plans to scale its B-Right AI Platform with the aim of setting a new global standard of care in prenatal ultrasound.
With increasing demand for AI-driven tools in healthcare, the company believes its regulatory foundation and clinical results position it strongly for international growth.
Leadership focused on improving outcomes for families and clinicians
Cécile Dupont, CEO of BrightHeart and Partner at Sofinnova Partners, said the funding will help accelerate the company’s mission to make AI a standard part of prenatal ultrasound care.
She said the focus remains on improving diagnostic accuracy, supporting better outcomes for families and newborns, and streamlining workflows for healthcare professionals.
BrightHeart’s new investors, including Odyssée Venture and GO Capital, bring experience in supporting the international scale-up of regulated healthcare technologies.
Julien Andrieux, Partner at Odyssée Venture, highlighted the company’s strong clinical foundation in one of the most complex areas of prenatal imaging. Leïla Nicolas, Partner at GO Capital, added that BrightHeart’s combination of expert-level screening and seamless workflow integration positions it as a reference platform in prenatal ultrasound.
Backing from the congenital heart defect community
The participation of the Mussallem CHD Alliance, part of the Linda and Mike Mussallem Foundation, underlines BrightHeart’s role in improving early and accurate diagnosis for babies born with congenital heart defects.
Orin Herskowitz, President of the Mussallem CHD Alliance, said BrightHeart’s platform brings expert-level fetal heart screening closer to becoming a routine part of prenatal care, addressing a critical unmet need for families affected by CHD.s
As BrightHeart continues to scale its AI platform across the US and Europe, the company is positioning itself at the forefront of efforts to improve prenatal imaging, clinical confidence, and outcomes for newborns worldwide.